Skip to main content

Theseus Pharmaceuticals Inc(THRX-Q)
NASDAQ

Today's Change
Delayed Last Update

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results

PR Newswire - Thu Nov 3, 2022

All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe